# Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

> **NCT00005018** · PHASE4 · COMPLETED · sponsor: **Glaxo Wellcome** · enrollment: 150 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Hydroxyurea
- **DRUG:** Abacavir sulfate
- **DRUG:** Efavirenz
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00005018
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** —
- **Final completion:** 2000-10
- **Target enrollment:** 150 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005018, "Safety and Effectiveness of a Combination Anti-HIV Drug Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00005018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*